NewAmsterdam Pharma (NASDAQ:NAMS) Major Shareholder Nap B.V. Forgrowth Sells 29,846 Shares of Stock

NewAmsterdam Pharma (NASDAQ:NAMS) major shareholder Nap B.V. Forgrowth sold 29,846 shares of NewAmsterdam Pharma stock in a transaction dated Monday, December 30th. The shares were sold at an average price of $25.54, for a total transaction of $762,266.84. Following the completion of the sale, the insider now directly owns 10,656,172 shares in the company, valued at approximately $272,158,632.88. The trade was a 0.28 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Nap B.V. Forgrowth also recently made the following trade(s):

• On Thursday, December 26th, Nap B.V. Forgrowth sold 33,438 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $26.01, for a total transaction of $869,722.38.
• On Monday, December 23rd, Nap B.V. Forgrowth sold 25,132 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $25.49, for a total value of $640,614.68.
• On Friday, December 20th, Nap B.V. Forgrowth sold 49,772 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $25.60, for a total value of $1,274,163.20.
• On Wednesday, December 18th, Nap B.V. Forgrowth sold 100,728 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $26.10, for a total transaction of $2,629,000.80.
• On Thursday, December 12th, Nap B.V. Forgrowth sold 166,011 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $25.39, for a total transaction of $4,215,019.29.
• On Monday, November 18th, Nap B.V. Forgrowth sold 33,273 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $25.08, for a total transaction of $834,486.84.
• On Friday, November 15th, Nap B.V. Forgrowth sold 8,530 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $25.02, for a total transaction of $213,420.60.

NewAmsterdam Pharma Stock Up 1.0 %

NewAmsterdam Pharma stock opened at $25.96 on Friday. The firm’s 50-day moving average is $22.39 and its two-hundred day moving average is $19.30. NewAmsterdam Pharma has a 12-month low of $11.57 and a 12-month high of $27.29.

Analysts Set New Price Targets

Several research firms recently weighed in on NAMS. Scotiabank raised their price objective on NewAmsterdam Pharma from $35.00 to $47.00 and gave the company a “sector outperform” rating in a research note on Wednesday, December 11th. HC Wainwright started coverage on NewAmsterdam Pharma in a research note on Monday. They set a “buy” rating and a $48.00 price target for the company. Piper Sandler reissued an “overweight” rating and issued a $37.00 price objective on shares of NewAmsterdam Pharma in a research note on Monday, September 23rd. Needham & Company LLC restated a “buy” rating and set a $36.00 target price on shares of NewAmsterdam Pharma in a research report on Thursday, December 5th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $31.00 price target on shares of NewAmsterdam Pharma in a research report on Thursday, September 5th. Seven analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of “Buy” and a consensus target price of $38.17.

Institutional Trading of NewAmsterdam Pharma

A number of hedge funds have recently bought and sold shares of NAMS. JPMorgan Chase & Co. lifted its stake in shares of NewAmsterdam Pharma by 176.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 22,351 shares of the company’s stock worth $371,000 after purchasing an additional 14,280 shares during the period. Barclays PLC increased its stake in NewAmsterdam Pharma by 1,813.4% in the third quarter. Barclays PLC now owns 7,596 shares of the company’s stock valued at $126,000 after purchasing an additional 7,199 shares during the last quarter. Geode Capital Management LLC lifted its position in NewAmsterdam Pharma by 1.6% during the third quarter. Geode Capital Management LLC now owns 86,322 shares of the company’s stock worth $1,433,000 after buying an additional 1,399 shares during the period. M&T Bank Corp boosted its stake in NewAmsterdam Pharma by 54.1% in the 3rd quarter. M&T Bank Corp now owns 27,328 shares of the company’s stock worth $454,000 after buying an additional 9,593 shares during the last quarter. Finally, Frazier Life Sciences Management L.P. increased its stake in shares of NewAmsterdam Pharma by 5.1% during the 3rd quarter. Frazier Life Sciences Management L.P. now owns 12,855,194 shares of the company’s stock valued at $213,396,000 after acquiring an additional 628,251 shares during the last quarter. Institutional investors and hedge funds own 89.89% of the company’s stock.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.